---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-222750"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2026-05-14T11:05:16+00:00"
generated_at: "2026-05-14T11:12:01.068854+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyePoint receives third positive DSMC recommendation for Phase 3 wet AMD DURAVYU trials

## Summary
- DSMC recommends LUGANO and LUCIA continue without modification; all active treatment-arm patients have received second DURAVYU dose.
- Over 35% of patients have received third planned dose at Week 56; safety profile consistent with >190 patients across prior trials.
- Topline data from LUGANO expected mid-2026; LUCIA readout to follow shortly after.
- Trials enroll over 900 patients; primary endpoint is non-inferiority in mean BCVA change at weeks 52 and 56.

## SEC filing metadata
- accession: 0001193125-26-222750
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2026-05-14T11:05:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/0001193125-26-222750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-222750
- JSON: https://secwatch.observer/filing/0001193125-26-222750.json
- Plain text: https://secwatch.observer/filing/0001193125-26-222750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.